High inflammatory activity related to the number of metabolic syndrome components

Journal of Clinical Hypertension

Volumn 12, Issue 2, 2010, Pages 136-144

  Kirilmaz, Bahadir ^a   Asgun, Fatih ^a   Alioglu, Emin ^b   Ercan, Ertugrul ^a   Tengiz, Istemihan ^b   Turk, Ugur ^b   Saygi, Serkan ^c   Özerkan, Filiz ^d  

^a ÇANAKKALE ONSEKIZ MART UNIVERSITY   (Turkey)

^b Central Hospital Izmir   (Turkey)

^c Karsi dotless yaka State Hospital   (Turkey)

^d EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; ALBUMIN; C REACTIVE PROTEIN; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; URIC ACID;

ABDOMINAL OBESITY; ADULT; AGE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FIBRINOGEN BLOOD LEVEL; FLOW MEDIATED DILATATION; GLUCOSE BLOOD LEVEL; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; INFLAMMATION; LEUKOCYTE COUNT; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL; URINARY EXCRETION; VASODILATATION;

BLOOD CELL COUNT; BODY MASS INDEX; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; FEMALE; FIBRINOGEN; HUMANS; HYPERTENSION; INFLAMMATION; INTERLEUKIN-6; LOGISTIC MODELS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MODELS, BIOLOGICAL; RISK FACTORS; STATISTICS AS TOPIC; URIC ACID;

EID: 75949124215     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2009.00229.x     Document Type: Article

References (48)

1. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
2. Festa A, D'Agostino R, Howard G. Choronic subclinical inflammation as part of the insulin resistance syndrome The Insulin Resistance Study (IRAS). Circulation 2000, 102:42-47.
3. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999, 340:115-126.
4. Hansson G, Libby P. The Role of the Lymphocyte: Atherosclerosis and Coronary Artery Disease 1997, 557-568. New York, NY, Lippincott Raven
5. Libby P, Simon DI. Inflammation and thrombosis: the clot thickens. Circulation 2001, 103:1718-1720.
6. Sahn DJ, DeMaria A, Kisslo J. The Committee on M-mode standardization of the American Society of Echocardiography: recommendations regarding quantitation in M- mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978, 58:1072-1083.
7. Devereux RB, Alonso DR, Lutas EM. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986, 57:450-458.
8. Savage DD, Levy D, Dannenberg AL. Association of echocardiographic left ventricular mass with body size, blood pressure and physical activity (The Framingham Study). Am J Cardiol 1990, 65:371-376.
9. Levy D, Savage DD, Garrison RJ. Echocardiographic criteria for left ventricular hypertrophy: the Framingham Heart Study. Am J Cardiol 1987, 59:956-960.
10. Daniels SR, Kimball TR, Morrison JA. Indexing left ventricular mass to account for differences in body size in children and adolescents without cardiovascular disease. Am J Cardiol 1995, 76:699-701.
11. Corretti MC, Anderson TJ, Benjamin EJ. International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002, 39(2):257-265.
12. Das UN. Mini-review: Is metabolic syndrome X an inflammatory condition? Exp Biol Med 2002, 227:989-997.
13. Björntorp P, Rosmond R. The metabolic syndrome: a neuroendocrine disorder? Br J Nutr 2000, 83(suppl 1):S49-S57.
14. Ford ES. A comparison of the prevalence of the metabolic syndrome using two proposed definitions. Diabetes Care 2003, 26:575-581.
15. Henry RR. Glucose control and insulin resistance in non-insulin-dependent diabetes mellitus. Ann Intern Med 1996, 124:97-103.
16. Valdez R, Athens MA, Thompson GH. Birth weight and adult health outcomes in a bietnich population on the USA. Diabetologia 1994, 37:624-631.
17. Jaquet D, Gaboruai A, Czernichow P. Insulin resistance early in adulthood in subjects with intrauterine growht retardation. J Clin Endocrinol Metab 2000, 85:1401-1406.
18. Hales CN, Barker DJ, Clark PM. Fetal and infant growth and impaired glucose tolerance at age of 64. Br Med J 1991, 303:1019-1022.
19. Bennett PH. Diabetes mellitus in Pima Indians. Lancet 1971, 2:488-489.
20. Howard BV, Lee ET, Pettit DJ. Plasma and lipoprotein cholesterol and triglyceride concentrations in the Pima Indians: distributions differing from those of Caucasians. Circulation 1983, 68:714-724.
21. Collins V, Dowse G, Finch C. An inconsistent relationship between insulin and blood pressure in three Pacific Island populations. J Clin Epidemiol 1990, 43:1369-1378.
22. Saad MF, Lillioja S, Nyomba B. Racial differences in the relation between blood pressure and insulin resistance. N Engl J Med 1991, 324:733-739.
23. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: Findings from the Third National Health and Nutrition Examination Survey. JAMA 2002, 287:356-359.
24. Pearson TA, Mensah GA, Alexander RW. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003, 107:499.
25. Kang ES, Kim HJ, Ahn CW. Relationship of serum high sensitivity C-reactive protein to metabolic syndrome and microvascular complications in type 2 diabetes. Diabetes Res Clin Pract 2005, 69(2):151-159.
26. Frohlich M, Imhof A, Breg G. Association between C-reactive protein and features of metabolic syndrome: a population based study. Diabetes Care 2000, 23(12):1835-1839.
27. Tchernof A, Lamarche B, Prud'Homme D. The dense LDL phenotype: association with plasma lipoprotein levels, visceral obesity, and hyperinsulinemia in men. Diabetes Care 1996, 19:629-637.
28. Taylor SI, Cama A, Accili D. Mutations in the insulin receptor gen. Endocr Rev 1992, 13:566-595.
29. Muller-Wieland D, Taub R, Tewari DS. Insulin receptor gene and its expression in patients with insulin resistance. Diabetes 1989, 38:31-38.
30. Prochazka M, Lillioja S, Tait JF. Lingake of chromosomal markers on 4q with a putative gene determining maximal insulin action in Pima Indians. Diabetes 1993, 42:514-519.
31. Baier LJ, Sacchettini JC, Knowler WC. An amino acid subsitution in the human intestinal fatty acid binding, increased fat oxidation, and insulin resistance. J Clin Invest 1995, 95:1281-1287.
32. Ikonomidis I, Andreotti F, Economou E. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation 1999, 100:793-798.
33. Ridker PM, Rifai N, Pfeffer MA. Long term effects of pravastatin on plasma concentration of C-reactive protein: the Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999, 100:230-235.
34. Groop L. Metabolic consequences of a family history of NIDDM (The Botnia Study): evidence for sex-specific parental effects. Diabetes 1996, 45:1585-1593.
35. Bjorntorp P, Rosmond R. The metabolic syndrome: a neuroendocrine disorder? Br J Nutr 2000, 83:49-57.
36. Fernadez-Real JM, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev 2003, 24(3):278-301.
37. Das UN. Is metabolic syndrome X an inflammatory condition? Exp Biol Med 2002, 227:989-997.
38. Mohemad-Ali V, Goodrick S, Rawesh A. Subcutaneous adipose tissue releases interleukin-6, but not tumour necrosis factor-α, in vivo. J Clin Endocrinol Metab 1997, 82:4196-4200.
39. Baumann H, Gauldie J. The acute phase response. Immunol Today 1994, 15:74-80.
40. Onat A, Ceyhan K, Sansoy V. Erişkinlerimizin yari dotless si dotless nda bulunan Dislipidemi ve metabolik sendromun özellikleri ve kombine hiperlipidemi ile ilişkisi. Turk Kardiyol Dern Ars 2001, 29:274-285.
41. Jialal I, Deveraj S. Inflammation and atherosclerosis: the value of the high sensitive C-reactive protein assay as a marker. Am J Clin Pathol 2001, 116((suppl 1)):108-115.
42. Vigushin DM, Pepys MB, Hawkins PN. Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. J Clin Invest 1993, 91:1351-1357.
43. Pasceri V, Willerson JT, Yeh EHT. Direct pro-inflammatory effect of C-reactive protein on human endotelial cells. Circulation 2000, 102:2165-2168.
44. Volanakis JE. Human C-reactive protein: expression, structure, and function. Mol Immunol 2001, 38:189-197.
45. Petne JR, Ueda S, Webb DJ. Endothelial nitric oxide production and insulin sensitivity: a physiological link with implications for pathogenesis of cardiovascular disease. Circulation 1996, 93:1331-1333.
46. Steinberg HO, Chaker H, Learning R. Obesity/insulin resistance is associated with endothelial dysfunction Implications for the syndrome of insulin resistance. J Clin Invest 1996, 97:2601-2610.
47. Duygu H. Endothelial functions and hypertension. J Card Res 2007, 5:90-98.
48. Hsueh WA, Law RE. Cardiovascular risk continuum: implications of insulin resistance and diabetes. Am J Med 1998, 105:4S-14S.